Grail reported Q1 revenue growth of 28% year over year to $40.8 million, driven by continued expansion of its Galleri multi-cancer screening test. Galleri revenue rose 37% to $39.8 million, while test volume climbed 50% to more than 56,000 tests, with self-pay accounting for more than two-thirds of volume.